Background {#Sec1}
==========

Approximately 6 million people live with heart failure (HF) in the United States \[[@CR1]\]. Understanding features of incident HF, such as risk factors for its development, can inform prevention and screening efforts and thus mitigate the effects of the HF epidemic. Studies to date examining incident HF have provided insight into key features, but have been limited to select populations. For example, reports from community-based cohorts in Olmstead County, Minnesota \[[@CR2]\] and Framingham, Massachusetts \[[@CR3]\] have described predominantly White populations; and reports from randomized-controlled trials have described populations that meet strict inclusion criteria, excluding many older adults and individuals with comorbidities \[[@CR4], [@CR5]\]. While studies from multicenter observational cohorts like the Cardiovascular Health Study (CHS), \[[@CR6]\] Dynamics of Health, Aging, and Body Composition study (Health ABC), \[[@CR7]\] and the Atherosclerosis Risk in Communities study (ARIC) \[[@CR8]\] have reported on more racially and ethnically diverse populations, study subjects originated from select communities which do not necessarily reflect the rest of the United States. Consequently, there is a need to examine incident HF using a contemporary racially and geographically diverse United States cohort. The REasons for Geographic And Racial Differences in Stroke (REGARDS) study \[[@CR9]\] is a cohort of over 30,000 community-dwelling African American and white adults from across the 48 contiguous United States, and is thus larger than CHS and Health ABC, and more geographically-diverse than ARIC. With a rigorous adjudication process for identifying cardiovascular events, this cohort has been used to describe incident stroke \[[@CR9]\] and incident myocardial infarction \[[@CR10]\]. In light of shared risk factors between these conditions and HF, the REGARDS cohort is particularly well-suited for describing incident HF as well. Given its racial and geographic diversity, large sample size, extensive covariate assessment, and longitudinal follow-up, the REGARDS cohort has the potential to provide generalizable insights on incident HF. In order to distinguish incident from prevalent HF, it is necessary to assemble a cohort free of HF at baseline. Accordingly, we aimed to develop and validate a simple medication-based strategy for assembling a HF-free cohort within REGARDS.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

The REasons for Geographic And Racial Differences in Stroke (REGARDS) study includes 30,239 African American and white men and women recruited from the 48 contiguous United States between 2003 and 2007 \[[@CR9]\]. The REGARDS cohort was devised to study antecedents of racial and geographic differences in stroke mortality in the United States. Participants were community-dwellers who self-identified as white or African American and had to be age ≥ 45 years at enrollment. Participants were enrolled in 2003--2007 using a stratified random sampling approach that balanced race, sex, and geographic location, with planned oversampling of the Southeastern United States, where the burden of cardiovascular disease is high. All participants completed a 45-minute baseline telephone interview ascertaining details of medical history, followed by an in-home visit collecting blood and urine samples as well as physiologic data (blood pressure, height and weight, electrocardiogram). REGARDS participants are additionally linked to Medicare claims data using Social Security numbers, sex, and date of birth as previously described \[[@CR11]\]. All REGARDS participants provided written informed consent and signed medical record release forms allowing REGARDS investigators to retrieve medical records for research purposes. The Institutional Review Boards of the University of Alabama at Birmingham and Weill Cornell Medicine approved this research.

Baseline REGARDS data collection {#Sec4}
--------------------------------

REGARDS participants completed a computer-assisted telephone interview which collected information on sociodemographics and medical history. Following the interview, a trained health technician performed an in-home examination to collect blood and urine specimens, measure blood pressure, conduct an electrocardiogram, and record an inventory of medications used by the participants. Age, race, sex, need to sleep on multiple pillows (orthopnea), and waking at night because of breathlessness (paroxysmal nocturnal dyspnea; PND) were self-reported. Atrial fibrillation was assessed based on self-reported diagnosis or atrial fibrillation recorded during the electrocardiogram. Hypertension was assessed based on self-reported use of medications to control blood pressure or measured blood pressure greater than 140 mmHg systolic or 90 mmHg diastolic.

Assembly of a HF-free cohort within REGARDS {#Sec5}
-------------------------------------------

Among the 30,239 eligible participants in REGARDS, we excluded 56 participants with anomalous data and 469 with no follow-up beyond the baseline assessment. We also excluded 686 participants with missing data on self-reported atrial fibrillation, 135 participants with missing data on baseline medication use, and 9 participants who had adjudicated HF hospitalizations between the baseline telephone interview and the in-home study visit. The remaining cohort included 28,884 eligible participants (Fig. [1](#Fig1){ref-type="fig"}a). To assemble a HF-free cohort within REGARDS, we developed a medication-based exclusion cascade, excluding participants with suspected HF using REGARDS study variables that indicated potential treatment for HF. As shown in Fig. [1](#Fig1){ref-type="fig"}, we excluded suspected HF by excluding participants taking HF-specific medications (any of the following: digoxin in the absence of atrial fibrillation, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker plus beta-blocker in the absence of hypertension; carvedilol; spironolactone; loop diuretics including furosemide, bumetanide, or torsemide; and/or a combination of hydralazine and nitrates). Fig. 1Exclusion cascade to assemble a heart failure-free cohort. First, we excluded those with anomalous data and those with missing follow-up. We then sequentially excluded suspected heart failure by excluding participants HF-specific medications (any of the following: digoxin in the absence of atrial fibrillation; angiotensin-converting enzyme inhibitor/angiotensin receptor blocker plus beta-blocker in absence of hypertension; carvedilol; spironolactone; loop diuretics including furosemide, bumetanide, or torsemide; and/or combination of hydralazine and nitrates). Abbreviations: *AF* Atrial fibrillation, *HF* Heart failure

HF hospitalizations among the REGARDS study sample {#Sec6}
--------------------------------------------------

REGARDS participants were followed through telephone calls twice per year. Participants were asked to report if they had been hospitalized and if so, the reason for hospitalization. Medical records were retrieved for hospitalizations suspected to be associated with select conditions including HF. Medical records were independently reviewed and adjudicated by two clinician-investigators and disagreements were resolved by committee. Adjudicators determined whether HF was present during the hospitalization based on signs and symptoms of HF, imaging findings, and biomarkers such as b-type natriuretic peptide.

Validation cohort {#Sec7}
-----------------

To validate our medication-based assembly of a HF-free cohort, we identified a subset of REGARDS participants who had at least six months of available Medicare fee-for-service inpatient and outpatient claims data at the time of the baseline in-home study examination (*n* = 10,340) \[[@CR11]\]. Medicare is a federal health insurance program in the United States that covers inpatient and outpatient care for adults aged 65 and older and younger individuals with disabilities or end-stage renal disease. It is estimated that about 80% of adults with HF in the United States are Medicare beneficiaries \[[@CR12]\]. The Medicare program is funded through income tax, premiums paid by Medicare beneficiaries, and the federal budget. Individuals can opt for fee-for-service coverage which requires copays or privately managed care with a variety of fee structures. Because claims for the privately managed programs were not available, this study is limited to individuals with fee-for-service coverage at the time of study entry. We additionally excluded 267 participants with missing data on self-reported atrial fibrillation, 8 participants with missing data on baseline medication use, and 6 participants who had adjudicated HF hospitalizations between the baseline telephone interview and the in-home study visit. The remaining cohort included 10,059 eligible participants (Fig. [1](#Fig1){ref-type="fig"}b).

Referent definitions of HF for evaluation {#Sec8}
-----------------------------------------

To assess the validity of our approach to assemble a HF-free cohort, we created 3 Medicare claims-based definitions of HF to serve as referent comparators. First, we defined a HF hospitalization as at least one inpatient claim for a principal diagnosis of HF ("Hospitalization for HF"). Secondly, we defined a principal diagnosis of HF as at least one inpatient claim with a principal discharge diagnosis of HF or at least two claims for outpatient physician visits (including emergency department visits) with principal diagnoses of HF ("Principal diagnosis of HF"). Finally, we defined "any diagnosis" of HF as at least one inpatient claim or two claims for outpatient physician visits where HF was a principal or secondary diagnosis ("Any diagnosis of HF"). During the period when REGARDS participants were enrolled (2003--2007), the United States used the *International Classification of Diseases*, 9th revision, Clinical Modification (ICD-9-CM). We defined HF according to ICD-9-CM diagnosis codes 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93, and 428.xx, as used by the Centers for Medicare & Medicaid Services for publicly reporting HF quality measures \[[@CR13]\]. Claims-based definitions of HF were based on all available Medicare claims from prior to the in-home visit date (minimum of 6 months).

Statistical analysis {#Sec9}
--------------------

We first compared the characteristics of participants included and excluded from the HF-free cohort using means and standard deviations for continuous variables and numbers and percentages for categorical variables. Among the population with linked Medicare claims, we calculated negative predictive value using each of the 3 Medicare claims-based definitions of HF as the referent. The negative predictive value represents the proportion of the HF-free cohort who did not have evidence of HF based on Medicare claims, and is thus the most important diagnostic performance parameter for assembling a HF-free cohort. We also calculated sensitivity, specificity, and positive predictive values for each of the 3 Medicare claims-based definitions. We calculated 95% confidence intervals using the normal approximation. In addition, we examined the performance of the HF-free cohort stratified by subgroups chosen a priori. These subgroups were based on age (≥75 versus 65--75 years of age), sex, and race. Analyses were conducted using SAS 9.4 (Cary, NC).

We also conducted sensitivity analyses to determine the incremental value of additionally excluding participants with self-reported orthopnea and/or PND from the HF-free cohort, as well as the incremental value of additionally excluding participants with adjudicated HF hospitalization within one year of follow-up.

Results {#Sec10}
=======

Study population {#Sec11}
----------------

The study sample was comprised of 28,884 eligible REGARDS participants. Among them, 25,759 participants (89%) did not take HF-specific medications and were therefore included in the HF-free cohort. Characteristics of the HF-free cohort and the 3125 who were excluded due to suspected HF are shown in Table [1](#Tab1){ref-type="table"}A. Notably, participants excluded due to suspected HF had a higher prevalence of several comorbid conditions including coronary artery disease, myocardial infarction, atrial fibrillation, hypertension, and diabetes compared to participants in the HF-free cohort. The HF hospitalization rate for the entire study sample was 6.29 per 1000 person-years (Table [2](#Tab2){ref-type="table"}). Events were 6-fold more likely among individuals who were excluded (26.6 per 1000 person-years) compared to those included in the HF-free cohort (4.29 per 1000 person-years). Table 1Characteristics of REGARDS participantsA. Among eligible REGARDS participantsEligible REGARDS ParticipantsHF-Free CohortSuspected HFNumber28,88425,7593125Age, mean (SD)64.9 (9.4)64.5 (9.3)68.4 (9.3)Female Sex15,875 (55.0%)14,161 (55.0%)1714 (54.9%)African American11,823 (40.9%)10,295 (40.0%)1528 (48.9%)BMI, mean (SD)29.3 (6.2)28.9 (5.9)32.3 (7.4)Coronary artery disease^a^5040 (17.6%)3711 (14.5%)1329 (43.2%)Myocardial infarction^a^3571 (12.5%)2605 (10.2%)966 (31.5%)Atrial fibrillation2540 (8.8%)1894 (7.4%)646 (20.7%)Stroke^a^1813 (6.3%)1374 (5.4%)439 (14.1%)Diabetes^a^6078 (21.8%)4684 (18.9%)1394 (46.3%)ACR ≥ 30^a^4154 (15.1%)3318 (13.5%)836 (28.6%)eGFR \< 60^a^3139 (11.3%)2277 (9.2%)862 (29.4%)Hypertension17,101 (59.2%)14,704 (57.1%)2397 (76.7%)Dyslipidemia^a^16,495 (59.3%)14,358 (57.8%)2137 (71.3%)Chronic lung disease2656 (9.2%)2159 (8.4%)497 (15.9%)B. Among Medicare based Validation CohortValidation CohortHF-Free CohortSuspected HFNumber10,05984921567Age, mean (SD)71.4 (7.3)71.3 (7.2)71.6 (8.1)Female Sex5160 (51.3%)4355 (51.3%)805 (51.4%)African American3519 (35.0%)2842 (33.5%)677 (43.2%)BMI, mean (SD)28.7 (5.9)28.2 (5.5)31.4 (7.0)Coronary artery disease2517 (25.0%)1764 (20.8%)753 (48.1%)Myocardial infarction1693 (16.8%)1169 (13.8%)524 (33.4%)Atrial fibrillation1144 (11.4%)792 (9.3%)352 (22.5%)Stroke904 (9.0%)658 (7.7%)246 (15.7%)Diabetes2407 (23.9%)1713 (20.2%)694 (44.3%)ACR ≥ 301767 (17.6%)1327 (15.6%)440 (28.1%)eGFR \< 602213 (22%)1628 (19.2%)585 (37.3%)Hypertension6652 (66.1%)5458 (64.3%)1194 (76.2%)Dyslipidemia6147 (61.1%)5069 (59.7%)1078 (68.8%)Chronic lung disease1100 (10.9%)834 (9.8%)266 (17.0%)^a^Percentages were determined after excluding participants with missing data for the given variableAbbreviations*ACR* Albumin-to-creatinine ratio*BMI* Body mass index*eGFR* Estimated glomerular filtration rate*HF* Heart failure*REGARDS* REasons for Geographic And Racial Differences in Stroke*SD* Standard deviationTable 2Heart failure hospitalization rates in REGARDS participantsEligible REGARDS SampleHF-Free CohortSuspected HFNumber of participants28,88425,7593125Heart Failure Hospitalizations, N1375855520Rate per 1000 person-years (95% Confidence Interval)6.29 (5.96, 6.62)4.29 (4.01, 4.58)26.6 (24.3, 28.9)Abbreviations*REGARDS* REasons for Geographic And Racial Differences in Stroke*HF* Heart failure

Medicare-based validation of HF-free cohort {#Sec12}
-------------------------------------------

The validation cohort was comprised of 10,059 eligible REGARDS participants. Compared to the broader REGARDS cohort, patients in the validation cohort were older and had a slightly higher prevalence of several comorbid conditions. Among the validation cohort, 8492 participants (84%) did not take HF-specific medications and were therefore included in the HF-free cohort. Characteristics of the HF-free cohort and those who were excluded due to suspected HF based on diagnosis codes are shown in Table [1](#Tab1){ref-type="table"}B. Similar to the observation in the broader study population, participants excluded due to suspected HF had a higher prevalence of coronary artery disease, myocardial infarction, atrial fibrillation, hypertension and diabetes compared to participants in the HF-free cohort.

Depending on the diagnostic-code definition used as the referent, the negative predictive value of the medication based approach to identifying a HF-free cohort ranged from 95.0--99.2% (Table [3](#Tab3){ref-type="table"}). The negative predictive value represents the proportion of the HF-free cohort who did not have evidence of HF based on Medicare claims. Using the most stringent referent definition (Medicare claims for hospitalization with HF as the principal diagnosis), 0.8% of the HF-free cohort had evidence of a history of HF at baseline. Using the least stringent definition (Medicare claims for inpatient or outpatient care with a HF diagnosis), 5% of the HF-free cohort had evidence of a HF history at baseline (3.8% with a principal diagnosis and 1.2% with a secondary diagnosis). This translated into the inclusion of just 64 to 426 participants with a Medicare-based diagnosis of HF (depending on the referent used) into the HF-free cohort. Table 3Diagnostic performance (95% confidence intervals) of heart failure-free cohort compared to Medicare referent standardsHF according to Medicare\
N (%)Excluded from HF-free cohort\
NIncluded in HF-free cohort\
NNPV %PPV %Sens %Spec %Hospitalization for HF**+**293 (2.9%)2296499.2% (99.1--99.4%)14.6% (12.9--16.4%)78.2% (73.4--82.9%)86.3% (85.6--87.0%)(**--**9766 (97.1%)13388428Principal diagnosis of HF**+**968 (9.6%)64232696.2% (95.8--96.6%)41.0% (38.5--43.4%)66.3% (63.3--69.3%)89.8% (89.2--90.4%)**--**9091 (90.4%)9258166Any diagnosis of HF**+**1135 (11.3%)70942695.0% (94.5--95.4%)45.2% (42.8--47.7%)62.5% (59.6--65.3%)90.4% (89.8--91.0%)**--**8924 (88.7%)8588066Abbreviations*HF* Heart failure*NPV* Negative predictive value*PPV* Positive predictive value*Sens* Sensitivity*Spec* Specificity

Specificity ranged from 86.3--90.4%, and sensitivity ranged from 62.5--78.2% (Table [3](#Tab3){ref-type="table"}). The number of participants without a Medicare-based diagnosis of HF excluded from our cohort ranged from 858 to 1338 depending on referent used. Notably, performance was stable across age, sex, and race strata (Additional files [1](#MOESM1){ref-type="media"}, [2](#MOESM2){ref-type="media"}, and [3](#MOESM3){ref-type="media"}).

Sensitivity analysis {#Sec13}
--------------------

The incremental value of additionally excluding self-reported symptoms (orthopnea and/or PND) to assemble a HF-free cohort was limited; negative predictive value improved slightly, but at a sacrifice of excluding an additional thousand participants (Table [4](#Tab4){ref-type="table"}A). Similarly, additionally excluding adjudicated HF hospitalizations within one year of follow-up provided little incremental improvement to negative predictive value (Table [4](#Tab4){ref-type="table"}B). Table 4Sensitivity analysis for diagnostic performance (95% confidence intervals) compared to Medicare referent standardsA. With addition of self-reported symptoms (orthopnea and/or paroxysmal nocturnal dyspnea)HF according to MedicareN (%)Excluded from HF-free cohortNIncluded in HF-free cohortNNPV %PPV %Sens %Spec %Hospitalization for HF**+**293 (2.9%)2563799.5% (99.3--99.7%)9.5% (8.4--10.6%)87.4% (83.6--91.2%)75.1% (74.2--75.9%)**--**9766 (97.1%)24367330Principal diagnosis of HF**+**968 (9.6%)74622297.0% (96.6--97.4%)27.7% (26.0--29.4%)77.1% (74.4--79.7%)78.6% (77.8--79.4%)**--**9091 (90.4%)19467145Any diagnosis of HF**+**1135 (11.3%)83829796.0% (95.5--96.4%)31.1% (29.4--32.9%)73.8% (71.3--76.4%)79.2% (78.4--80.1%)**--**8924 (88.7%)18547070B. With addition of adjudicated heart failureHF according to MedicareN (%)Excluded from HF-free cohortNIncluded in HF-free cohortNNPV %PPV %Sens %Spec %Hospitalization for HF**+**293 (2.9%)2365799.3% (99.2--99.5%)14.6% (12.9--16.4%)80.5% (76.0--85.1%)85.9% (85.2--86.6%)**--**9766 (97.1%)13758391Principal diagnosis of HF**+**968 (9.6%)65731196.3% (95.9--96.7%)40.8% (38.4--43.2%)67.9% (64.9--70.8%)89.5% (88.9--90.1%)**--**9091 (90.4%)9548137Any diagnosis of HF**+**1135 (11.3%)72441195.1% (94.7--95.6%)44.9% (42.5--47.4%)63.8% (61.0--66.6%)90.1% (89.4--90.7%)**--**8924 (88.7%)8878037

Discussion {#Sec14}
==========

By excluding participants based on their use of HF-specific medications, we successfully assembled a cohort within REGARDS where very few participants had a history of HF. This HF-free cohort can be examined in the future to study incident HF among a contemporary geographically-diverse study sample. Notably, HF hospitalization rate for the HF-free cohort was one-sixth the rate for individuals excluded due to possible baseline HF. The HF hospitalization rate for the HF-free cohort was much lower than the rates observed in major HF trials, lending additional support for our approach of identifying a cohort free of HF \[[@CR14]\]. We further validated our approach using Medicare claims data as the referent, yielding excellent negative predictive value; negative predictive value remained above 95% regardless of the referent comparator.

Prior observational studies of HF-free cohorts used to identify and describe incident HF have included those derived from communities in Olmstead County, Minnesota \[[@CR2]\] and Framingham, Massachusetts, \[[@CR3]\] as well as multi-community cohorts from the CHS, \[[@CR6]\] Health ABC, \[[@CR7]\] and ARIC \[[@CR8]\]. These studies have developed HF-free cohorts by detecting and excluding HF based on self-report, in some cases followed by medical record review. The approach of identifying HF via self-report may be limited by suboptimal negative predictive value (86% in ARIC based on reported prevalence of 18.6%, sensitivity of 33% and specificity of 97%) \[[@CR15]\] and suboptimal reliability with reported kappa statistics as low as 0.44 \[[@CR16]\]. Our strategy of utilizing HF-specific medications to identify and exclude participants with HF obviated dependence on the self-reporting of HF, a substantial source of bias, and provided a practical method for assembling a HF-free cohort. This approach was particularly well-suited for the REGARDS study sample, in which medication history was collected at baseline via medication inventory, and was available in nearly 100% of the study sample.

Given the large number of pharmacologic agents that are indicated for use in HF, many of which are specific to HF, \[[@CR17], [@CR18]\] we speculated that leveraging HF medication use to identify (and subsequently exclude) participants with HF would provide a robust strategy for assembling a HF-free cohort. Given its excellent specificity for HF, \[[@CR19]\] we incorporated the use of digoxin in the absence of atrial fibrillation to identify and exclude participants from our HF-free cohort. To further capitalize on the concept of HF medication use in the absence of other (non-HF) indications, we also incorporated the use of neuro-hormonal blockers (renin-angiotensin inhibitors and beta blockers) in the absence of hypertension to identify and exclude participants from our HF-free cohort. Finally, we incorporated medications specific for HF that lacked other (non-HF) common guideline-based indications to identify participants with HF---we subsequently identified and excluded participants taking carvedilol which is a beta-blocker specifically indicated for HF, spironolactone which is an aldosterone inhibitor indicated for HF (of note, eplerenone use was exceedingly rare in this cohort), loop diuretics which are the preferred agents for decongestion, \[[@CR17]\] and pre-specified combinations of vasodilators (hydralazine and nitrates) indicated for use in HF.

Our approach of excluding participants with suspected HF based on their medication use optimized negative predictive value, the diagnostic performance parameter most important to assembling a HF-free cohort. In developing our strategy to assemble a HF-free cohort, we also considered the potential consequence of excessively excluding participants, which would limit the size and generalizability of the cohort, and could significantly hamper statistical power for future studies. Accordingly, our approach preserved a moderately-sized cohort of 25,759 participants. In sum, our strategy maximized negative predictive value without significantly sacrificing the size of the cohort.

HF affects a diverse population that includes varying age, men and women, and whites and African Americans \[[@CR1], [@CR20]\]. Prior studies have shown that prescribing patterns for HF may differ based on age, \[[@CR21]\] sex, \[[@CR22]\] and race \[[@CR23]\]. Accordingly, we examined the diagnostic performance of our medication-based strategy to assemble a HF-free cohort among age-, sex-, and race-related subgroups chosen a priori. Our findings revealed that performance was stable across both age strata, men and women, and whites and African Americans. This supports the use of our strategy to assemble a HF-free cohort, without evidence of bias related to age, sex, or race.

When screening for HF, symptomatology like orthopnea and PND are frequently assessed. We therefore examined the impact of incorporating these self-reported symptoms in our medication-based strategy. Our results revealed that orthopnea and/or PND did not substantively improve negative predictive value. This is consistent with limitations of performance observed for the diagnosis of HF in the clinical context \[[@CR24]\]. Thus, we concluded that, to identify and exclude participants with HF, our simple medication-based strategy did not benefit from the addition of self-reported symptoms.

There were some limitations to our study that should be noted. Sensitivity and positive predictive value were not particularly high; thus this strategy may be more appropriate for developing a HF-free cohort than for detecting HF. Although a medication inventory was collected for nearly all REGARDS participants, we cannot be certain that these were complete in all cases. Finally, Medicare is an imperfect referent due to limitations in the accuracy of claims-based diagnoses \[[@CR25]\]. Further, our study excluded REGARDS participants without Medicare, and we are unable to draw definitive conclusions about younger individuals with HF. Participants with available Medicare claims at baseline were older and had a higher prevalence of chronic medical conditions compared to the broader REGARDS study population.

Conclusion {#Sec15}
==========

Our investigation has assembled and validated a HF-free cohort in REGARDS, which can serve as the basis for future studies to examine incident HF in REGARDS and perhaps similar study samples. Our medication-based approach may be worth examining in other cohorts that have rigorous methods of data collection on medications to ascertain its generalizability. REGARDS in particular offers an excellent cohort for studying incident HF because it is a contemporary geographically diverse cohort with a large number of African American and white participants. Accordingly, through this HF-free cohort, REGARDS has the potential to provide insights on incident HF.
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